Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)


Wednesday 24 November, 2021

Oxford BioDynamics

PDMR Dealing

RNS Number : 4963T
Oxford BioDynamics PLC
24 November 2021

24 November 2021 


Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")


PDMR Dealing


Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Vulpes Life Sciences Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 100,000 Ordinary Shares of 1 pence each ("shares") at a price of 41.2p per share.


Following this transaction, Vulpes Life Sciences Fund is interested in 14,009,203 shares, representing 13.96% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 15,040,878 shares, representing approximately 14.99% of the Company's current issued share capital.  

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:



Details of the person discharging managerial responsibilities/person closely associated



Stephen Diggle


Reason for the notification



Non-Executive Director


Initial notification/ Amendment 

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Oxford BioDynamics Plc 





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each


ISIN:  GB00BD5H8572


Nature of the transaction

Acquisition of ordinary shares


Price(s) and volume(s)









Aggregated information

- Aggregated volume

- Price










Dates of the transactions

22 November 2021


Place of the transaction

Outside a trading venue





For further details please contact:


Oxford BioDynamics Plc

Jon Burrows, CEO

Paul Stockdale, CFO


+44 (0)1865 518910

Shore Capital

Nominated Adviser and Broker

Stephane Auton

John More


+44 (0)20 7408 4090

Instinctif Partners

Tel: +44 (0)20 7457 2020

Melanie Toyne-Sewell / Nathan Billis

[email protected]


Notes for Editors


About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

In March 2021, the Company launched its first commercial prognostic test,  EpiSwitch ®   CST  (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery,  EpiSwitch® Explorer Array Kit . Its next product will be EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, , or follow on Twitter or LinkedIn .

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t